Clinical trial
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Phase 1b Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL747 in Subjects With Alzheimer's Disease
NCT03757325 is registered in ClinicalTrials.gov with Denali Therapeutics Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Phase 1b Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL747 in Subjects With Alzheimer's Disease
- Lead sponsor
- Denali Therapeutics Inc.
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- February 13, 2019
- Completion date
- December 5, 2019
- Enrollment
- 16 (actual)
- Sites
- 5
Conditions
As the registry lists them; a condition with its own page is linked.